Pediatrics at CU School of Medicine is among the best in the nation! World-class pediatric residency program and research facilities. Department of Pediatrics, University of Colorado School of Medicine, Children's Hospital Colorado

MERTK receptor tyrosine kinase is a therapeutic target in melanoma.

Schlegel J, Sambade MJ, Sather S, Moschos SJ, Tan AC, Winges A, Deryckere D, Carson CC, Trembath DB, Tentler JJ, Eckhardt SG, Kuan PF, Hamilton RL, Duncan LM, Miller CR, Nikolaishvili-Feinberg N, Midkiff BR, Lui J, Zhang W, Yang C, Wang X, Frye SV, Earp HS, Shields JM, Graham DK.

J Clin Invest. 2013 May1;123(5)

Inhibition of MerTK increases chemosensitivity and decreases oncogenic potential in T-cell acute lymphoblastic leukemia.

Brandao LN, Winges A, Christoph S, Sather S, Migdall-Wilson J, Schlegel J, McGranahan A, Gao D, Liang X, Deryckere D, Graham DK.

Blood Cancer J. 2013 Jan 25;3:e101

Christoph S, Schlegel J, Alvarez-Calderon F, Kim YM, Brandao LN, Deryckere D, Graham DK.

J Hematol Oncol. 2013 Jan 23;6:10

Mer or Axl receptor tyrosine kinase inhibition promotes apoptosis, blocks growth and enhances chemosensitivity of human non-small cell lung cancer.

Linger RM, Cohen RA, Cummings CT, Sather S, Migdall-Wilson J, Middleton DH, Lu X, Barón AE, Franklin WA, Merrick DT, Jedlicka P, Deryckere D,Heasley LE, Graham DK.

Oncogene. 2012 Aug 13

Prolonged exposure to a Mer ligand in leukemia: Gas6 favors expression of a partial Mer glycoform and reveals a novel role for Mer in the nucleus.

Migdall-Wilson J, Bates C, Schlegel J, Brandão L, Linger RM, DeRyckere D, Graham DK.

PLoS One. 2012;7(2):e31635

TAM receptors in leukemia: expression, signaling, and therapeutic implications.

Brandão L, Migdall-Wilson J, Eisenman K, Graham DK.

Crit Rev Oncog. 2011;16(1-2):47-63.

Targeting paediatric acute lymphoblastic leukaemia: novel therapies currently in development.

Taking aim at Mer and Axl receptor tyrosine kinases as novel therapeutic targets in solid tumors.